- GL Stock Near 52-Week High: A Signal for Investors to Hold Tight?
May 11, 2026
Shares of Globe Life Inc. GL closed at $151.08 on Friday, near its 52-week high of $156.69. This proximity underscores investor confidence. It has the ingredients for further price appreciation. The stock is trading above the 50-day and 200-day simple moving averages (SMA) of $145.42 and $140.34, respectively, indicating solid upward momentum. SMA is a widely used technical analysis tool to predict future price trends by analyzing historical price data.
Earnings of Globe Life grew 16.1% in the last five years, better than the industry average of 0.6%. GL has a solid surprise history. The stock has a solid track record of beating earnings estimates in two of the last four quarters while missing in the other two, with an average being 1.06%.Zacks Investment Research
Image Source: Zacks Investment Research
GL is an Outperformer
Shares of Globe Life have gained 25.1% in the past year, outperforming its industry and the Finance sector’s growth of 6.1% and 12.2%, respectively.
GL has outperformed its peers, Aflac Incorporated AFL and Unum Group UNM, which have risen 7.2% and 0.1%, respectively, in the past year, while AMERISAFE, Inc. AMSF has lost 35.9%.Zacks Investment Research
Image Source: Zacks Investment Research
GL Shares are Affordable
Globe Life shares are trading at a discount compared to the industry. Its forward price-to-earnings multiple of 9.53X is lower than the industry average of 12.65X, the Finance sector’s 15.79X and the Zacks S&P 500 Composite’s 22.16X. Also, it has a Value Score of A.
GL’s Growth Projection Encourages
The Zacks Consensus Estimate for Globe Life’s 2026 earnings per share indicates a year-over-year increase of 6.2%. The consensus estimate for revenues is pegged at $6.41 billion, implying a year-over-year improvement of 6.3%.
The consensus estimate for 2027 earnings per share and revenues indicates an increase of 7.8% and 6.1%, respectively, from the corresponding 2026 estimates.
Target Price Reflects Potential Upside
Based on short-term price targets offered by 13 analysts, the Zacks average price target is $173.23 per share. The average indicates a potential 13.6% upside from the last closing price.Zacks Investment Research
Image Source: Zacks Investment Research
GL’s Return on Capital
GL’s trailing 12-month return on equity is 20.9%, ahead of the industry average of 13.8%. Return on equity, a profitability measure, reflects how effectively a company is utilizing its shareholders’ equity.
Also, the return on invested capital (ROIC) in the trailing 12 months was 12.5%, better than the industry average of 6.6%. Its ROIC has been increasing over the last few quarters amid capital investment made over the same time frame. This reflects the company’s efficiency in utilizing funds to generate income.
Story Continues
Key Points to Note for Globe Life
Globe Life has been witnessing a positive trend in revenues, driven by premium growth in its Life Insurance and Health Insurance segments and net investment income.
The strong performance of the American Income and Liberty National divisions should drive the top line in the future. Liberty National is likely to continue to benefit from improved productivity and agent count. GL’s expansion initiatives to capture heavily populated and less penetrated areas should drive growth in the future.
Globe Life expects net life sales of mid-single-digit growth at American Income, low double-digit growth at Liberty National, and low single-digit growth at direct-to-consumer in 2026. The company expects Net health sales of mid-single-digit growth for Liberty National and low double-digit growth for Family Heritage in 2026. For United American, the company is currently projecting high-teens growth for 2026.
Moreover, net investment income continues to be another important driver of the company’s top-line growth and has been exhibiting improvement over the last few years. The metric is likely to keep growing, riding on improved invested assets and higher interest rates on new investments.
The company has maintained a strong liquidity position with sufficient cash-generation capabilities. Its operations comprise writing basic protection life and supplemental health insurance policies, which generate strong and stable cash flows. For 2025, Globe Life has targeted a consolidated Company Action Level RBC ratio of 300% to 320%.
A strong capital position enables Globe Life to enhance its shareholder value via share buybacks and dividend payouts. The insurer has continuously been increasing its dividend over the past eight years (2017-2024), witnessing a CAGR of 7%.
Conclusion
Globe Life’s higher life and health sales, improved invested assets, increased productivity and agent count, strong liquidity position and effective capital deployment make it an attractive stock.
Globe Life has a VGM Score of A. The VGM Score helps identify stocks with the most attractive value, best growth and the most promising momentum.
Higher return on capital, impressive dividend history, and solid growth projections should continue to benefit the insurer over the long term. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aflac Incorporated (AFL) : Free Stock Analysis Report
Unum Group (UNM) : Free Stock Analysis Report
AMERISAFE, Inc. (AMSF) : Free Stock Analysis Report
Globe Life Inc. (GL) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- How a Breast Cancer Diagnosis Inspired Check for Cancer Champion Adamari López
May 11, 2026
NORTHAMPTON, MA / ACCESS Newswire / May 11, 2026 / Originally published on Aflac Newsroom
At just 33 years old, Adamari López was thriving in her career and had quickly become a household name. She was successful, happy, healthy and felt unstoppable. It was then that an ordinary moment changed her life. During a regular self-exam, she discovered a lump that she couldn't ignore.
Like many women, she initially wondered if it was nothing - a hormonal change, stress, something temporary. A doctor suggested the same. But when the lump didn't go away and pain followed, Adamari listened to her instincts and returned for further testing.
Several doctor visits and tests later, she was faced with the unexpected, but unfortunately it happens more often than one might think, even at her age: a breast cancer diagnosis. Adamari's world quickly shifted from television studios and bright lights to doctor appointments and treatment that included surgery, chemotherapy and steps that would help preserve her fertility - choices that not only helped save her life, but helped give her the best chance at the future she knew she wanted beyond cancer. All were successful: Adamari is now a mom, cancer-free, back hard at work and mission-driven - milestones that once felt uncertain but now proudly define who Adamari is.
Survival with purpose: From patient to champion
Today, more than two decades after diagnosis, Adamari's life is full - as a writer, television personality, mother and survivor. Her journey inspired her and shaped her purpose to help empower people to take charge of their wellness, driving the importance of being proactive and persistent when it comes to routine health care.
"My main reason for speaking openly has always been to emphasize the importance of prioritizing your health - because you never know what life may bring," said Adamari. "By having these regular, open conversations about our health, we can have a positive impact on our families and communities to create a healthier, brighter future for everyone."
Adamari lives by example, instilling these same principles for her daughter, Alaïa, who speaks out herself about her mom's story. And it's because of this unwavering commitment to helping others understand the importance of proactive health that Adamari was honored as one of Aflac's inaugural Check for Cancer Champions - an exclusive group comprised of people who have demonstrated an extraordinary commitment to turning negatives into positives.
Cancer remains part of her story, not as a shadow, but as a catalyst. It reshaped how she measures success, deepened her empathy and clarified her mission. It's a message forged in survival, delivered with urgency and hope - and one she continues to share so that others may never have to learn it on their own. At the same time, Alaïa has been recognized by Aflac as a junior Check for Cancer Champion.
Story Continues
Helping break down cultural barriers
For many Hispanic families, health decisions are rarely made in isolation. According to the 2025 Aflac Wellness Matters Survey®, Hispanic men (86%) and Hispanic women (83%) are among the most likely to be swayed by a loved one urging them to act on their personal health. The study also found that one-third of U.S. Hispanics cited their mothers as their top advocate, underscoring the powerful role family plays in shaping these types of decisions.
"I'm deeply aware of how culture, language and access can shape health outcomes," said Adamari. "I don't just want the Latina community to be aware of the potential impact of cancer, I want them to feel empowered to have regular, open conversations, ask questions and seek care early - even if they feel fine."
For Adamari, fostering those conversations within families, across generations and in trusted spaces is essential to breaking down barriers and building a healthier future for the communities she has long represented - just another reason why Adamari is a champion.
The Check for Cancer Champions program is part of Aflac's Check for Cancer initiative, a bold, national movement to increase cancer screenings by 10% over 10 years. Learn more about the Check for Cancer movement by visiting Aflac.com/CheckForCancer.
Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999
Z2600296
EXP 5/27 Aflac Incorporated
Find more stories and multimedia from Aflac Incorporated at 3blmedia.com.
Contact Info:
Spokesperson: Aflac Incorporated
Website: https://www.3blmedia.com/profiles/aflac-incorporated
Email: info@3blmedia.com
SOURCE: Aflac Incorporated
View the original press release on ACCESS Newswire
View Comments
- Check for Cancer Champion Ernie Johnson Jr.'s Legacy Beyond Survival
May 6, 2026
NORTHAMPTON, MA / ACCESS Newswire / May 6, 2026 / Originally published on Aflac Newsroom
Sports fans immediately recognize his voice. Beloved broadcaster Ernie Johnson Jr. first graced the airwaves in 1979 and quickly became one of the most recognizable sports hosts and analysts. On air, his visible warmth, humor and humanity was welcomed in millions of living rooms across the nation and matched only by his persona off the air. Aflac Incorporated
Then, "it" happened.
Ernie's long cancer journey began quietly in 2003, at the young age of 47. He noticed swelling on the left side of his face. Admittedly, he delayed getting it checked out - after all, it was painless and didn't interfere with his work. Eventually, he saw his doctor, went through scans, biopsies and a bone marrow test before finally receiving a diagnosis: non-Hodgkin's lymphoma, a cancer of the lymphatic system, but also a wake-up call that transformed him from innocent bystander to the cancer epidemic into an active advocate. It was only the tip of his iceberg, as years later, prostate cancer would take hold as well.
Not just a survivor - a champion
This April, Ernie received an honor, becoming one of Aflac's inaugural Check for Cancer Champions. An exclusive group comprised of people who have demonstrated an extraordinary commitment to turning negatives into positives.
Though he is grateful for this recognition, there's a common phrase among those living with cancer that Ernie often expresses, "It's a club no one wants to belong to." It's through this reluctant association that he gained a new understanding of vulnerability, empathy and the importance of using his platform and voice to help others navigate their own journeys, starting with early detection. That's why he turned his own situation into an opportunity to fiercely advocate for cancer screenings and proactive health care. It is why he has been named a Check for Cancer Champion.
Using his voice to inspire others to check for cancer
Ernie doesn't cut around the edges when it comes to his advocacy. He urges people to face the "fear factor" of testing - avoidance is not a strategy. He encourages open conversations and uses his own experience as proof points. And for those diagnosed, he says, "You may have cancer, but it doesn't have you!"
Ernie is famous. He has a wonderful family and is beloved within and outside of his profession. He could easily have dealt with cancer in solitude. He had every right to say, "It's none of your business." But that is not Ernie. That's not the man who gives of himself in ways that are never discussed or publicized. It's not the guy who quietly gives back to his community, visits children at the nearby cancer center and motivates others to higher levels of altruism.
Story Continues
What he does is speak out. He says, "There's no shame in taking care of your health," reminding men that it is a sign of strength. He lends his name and bandwidth to organizations whose missions are to improve and save lives through advocacy awareness and support. He pulls no punches reminding Black men to prioritize early screening, as they are more likely than any others to be diagnosed with prostate cancer. And, extending his legacy of advocacy, Ernie and his wife Cheryl, cofounded the Love You Too Foundation to support vulnerable children and families facing various health‑related needs. Ernie Johnson Jr. helps save lives, and that makes him a champion.
The Check for Cancer Champions program is part of Aflac's Check for Cancer initiative, a bold, national movement to increase cancer screenings by 10% over 10 years. Learn more about the Check for Cancer movement by visiting Aflac.com/CheckForCancer.
Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999
Z2600275
EXP 4/27
Find more stories and multimedia from Aflac Incorporated at 3blmedia.com.
Contact Info:
Spokesperson: Aflac Incorporated
Website: https://www.3blmedia.com/profiles/aflac-incorporated
Email: info@3blmedia.com
SOURCE: Aflac Incorporated
View the original press release on ACCESS Newswire
View Comments
- Aflac: An Insurer To Buy After Impressive Q1 Results, Even As Valuation Rises
May 6, 2026 · seekingalpha.com
Aflac remains a Buy despite a Q1 earnings miss, supported by organic policy growth, proven dividend increases, and robust balance sheet strength. Growth catalysts include new policy sales, expanding Asian market presence, and niche segments like pet insurance, though revenue trends remain uneven. Margins and expense ratios are favorable, with A-level credit ratings and conservative leverage, but forward P/E multiples signal some overvaluation and more muted near-term upside.
- Why Aflac (AFL) Narrative Is Shifting As Analysts Reset Price Targets And Earnings Paths
May 3, 2026
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Aflac’s price target story right now is less about big moves and more about small reset points, with several firms trimming targets by US$2 to US$5 while others edge them higher toward US$118. Those shifts line up with cautious analyst commentary that pulls earnings expectations in a bit, yet still keeps ratings neutral and highlights room for modest upside rather than a sharply negative view. As you read on, you will see how to track these changing targets and what they might signal for Aflac’s evolving narrative.
Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Aflac.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
Wells Fargo lifted its Aflac price target to US$118 from US$109 and kept an Equal Weight rating, signaling that the firm still sees the shares as reasonably aligned with its view of fair value. Wells Fargo highlighted refreshed 2027 and 2028 EPS frameworks, which provides a longer runway of earnings assumptions that can support current valuation arguments if Aflac meets those guides.
🐻 Bearish Takeaways
Piper Sandler, Barclays, Mizuho, and UBS each trimmed Aflac price targets by US$2 to US$5, which reflects more cautious stances around execution and earnings, even if ratings are not aggressively negative. Keefe Bruyette reinitiated Aflac at Market Perform and later made a small price target increase, underscoring that some analysts see the risk or reward as balanced rather than skewed toward strong growth.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NYSE:AFL 1-Year Stock Price Chart
We've flagged 2 risks for Aflac. See which could impact your investment.
What's in the News
Aflac Re Bermuda Ltd. agreed with Japan Post Insurance Co. Ltd. to reinsure a block of whole life annuities through coinsurance, with Japan Post Insurance continuing to service and administer the policies from March 31, 2026. Aflac added a long term care rider to its Group Life Term to 120 product, combining term life coverage with long term care benefits for home based or facility based care, subject to state availability and underwriting entities. Empower Brokerage began an affiliation with Aflac, giving more than 8,000 partnering agents the ability to sell Aflac individual and group policies and providing support on contracting, commissions, and bonuses. From October 1, 2025 to December 31, 2025, Aflac repurchased 7,249,599 shares for US$800.12m, completing a program announced on August 8, 2017, under which 265,676,748 shares were bought back for US$17.66772b.
Story Continues
How This Changes the Fair Value For Aflac
Fair value estimate remains at US$111.86 per share with no change to the implied intrinsic value. Long term revenue growth assumption moves from 1.46% growth to a 0.14% decline. Net profit margin input adjusts from 20.75% to 20.86%. Future P/E multiple in the model shifts from 16.53x to 16.67x. Discount rate stays at 6.98% with no change to the required return used in the model.
Never Miss an Update: Follow The Narrative
Narratives link a company's real world story to a financial forecast and fair value, so you can see how news and fundamentals connect. They update over time as new data, guidance, and analyst assumptions come through.
Head over to the Simply Wall St Community and follow the Narrative on Aflac to stay up to date on:
How new cancer products in Japan, modular coverage, and expanded group benefits are widening Aflac's addressable market and cross sell potential. The role of digital underwriting, Gen AI tools, and direct to consumer channels in Japan and the U.S. in reshaping costs and distribution reach. Key risks tied to Japan premium pressure, higher technology and expense ratios, currency exposure, and slower U.S. sales momentum.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AFL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- AFL Q1 Deep Dive: Missed Expectations as Japan Sales Offset by Premium Pressure
May 2, 2026
Supplemental insurance provider Aflac (NYSE:AFL) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.8% year on year to $4.24 billion. Its non-GAAP profit of $1.75 per share was 2.5% below analysts’ consensus estimates.
Is now the time to buy AFL? Find out in our full research report (it’s free).
Aflac (AFL) Q1 CY2026 Highlights:
Revenue: $4.24 billion vs analyst estimates of $4.32 billion (1.8% year-on-year decline, 1.7% miss) Adjusted EPS: $1.75 vs analyst expectations of $1.80 (2.5% miss) Adjusted Operating Income: $1.12 billion vs analyst estimates of $1.19 billion (26.4% margin, 6% miss) Market Capitalization: $59.87 billion
StockStory’s Take
Aflac’s first quarter results fell short of Wall Street’s expectations, with both revenue and adjusted earnings per share missing consensus estimates. The market responded negatively, with shares declining after the announcement. Management highlighted strong sales momentum in Japan, particularly from new medical and cancer insurance products, but acknowledged ongoing challenges in maintaining earned premium growth. CEO Daniel Amos pointed to the company’s focus on persistency and distribution channel expansion as key operational themes, while CFO Max Broden discussed pressures from lapses and the impact of reinsurance transactions on near-term earnings.
Looking ahead, Aflac’s guidance is shaped by its ability to grow sales in both Japan and the U.S., while navigating persistency challenges and changes in customer mix. Management sees opportunity in expanding their reinsurance franchise in Japan and expects sales of core products to remain robust. However, CFO Max Broden cautioned that improving earned premium growth will require sustained sales momentum, stating, "We have a line of sight of getting to that level, but for the time being, we expect to remain in the range of negative 1% to 2% on underlying earned premium."
Key Insights from Management’s Remarks
Management attributed the quarter’s underperformance to softer earned premiums in Japan, higher lapses, and near-term headwinds from a new external reinsurance transaction, while emphasizing ongoing product momentum and disciplined cost control.
Japan product launches drive sales: Strong performance in Aflac Japan was fueled by new medical and cancer insurance products (Onsen Tallett and Miraito), with management noting a 25.5% increase in sales. However, this did not immediately translate into higher earned premiums due to persistency and lapses. Persistency and lapse dynamics: Persistency rates in Japan remained high but dipped slightly, while the mix of lapse and reissue activity shifted toward younger policies. Management explained that this trend has only a minor overall impact on long-term profitability, but acknowledged it can temporarily weigh on reported premium growth. U.S. group business momentum: In the United States, sales growth was led by group voluntary products, group life, and absence disability, with these segments up over 12% year-over-year. Core agent-driven business remained flat to slightly down, as Aflac continued investing in agent recruitment and onboarding. Expense management aids margins: Both Japan and the U.S. benefited from disciplined expense management, with Japan’s expense ratio improving year-over-year and the U.S. maintaining strong profitability despite higher amortization and advertising spend. Reinsurance strategy expands: Aflac executed its first third-party reinsurance deal in Japan, which management described as a strategic milestone. While the initial financial impact was minor, the company views this as a platform for future growth and diversification of earnings through additional reinsurance transactions.
Story Continues
Drivers of Future Performance
Aflac’s outlook is driven by product innovation, sales execution in Japan and the U.S., and selective expansion into reinsurance, but faces headwinds from persistency, premium growth challenges, and industry-wide cost pressures.
Japan premium growth hurdles: Management expects continued strong sales of new products in Japan, but acknowledges that lapses and reissues will keep underlying earned premium growth flat to slightly negative until sales volumes rise further. Aflac is targeting at least JPY 80 billion in annual sales to offset lapsation effects and return to premium growth. U.S. segment growth and channel mix: Growth in group voluntary and employer-based products is expected to continue, while the traditional agent channel remains under pressure. Management is focused on boosting agent conversion rates and improving onboarding processes to support this segment. Reinsurance and capital deployment: The company plans to selectively pursue additional reinsurance blocks in Japan to diversify earnings and utilize excess capital. Management stated these deals are expected to be accretive over time, but short-term earnings impact may be negative or neutral as new blocks ramp up.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will closely monitor (1) whether new product launches in Japan continue to drive sales momentum and begin to improve underlying earned premium growth, (2) progress in revitalizing the U.S. agent channel and sustaining group business gains, and (3) the scale and profitability of further reinsurance transactions in Japan. Additionally, we will track how persistency trends and cost controls impact margins across segments.
Aflac currently trades at $112.74, down from $116.21 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
View Comments
- Aflac Q1 Earnings Miss Estimates on Lower Investment Income
May 1, 2026
Aflac Incorporated AFL reported first-quarter 2026 adjusted earnings per share (EPS) of $1.75, which missed the Zacks Consensus Estimate by 2.9%. However, the bottom line improved 5.4% year over year.
Adjusted revenues totaled $4.2 billion, which declined 1.9% year over year. The top line missed the consensus mark by 2.1%.
AFL’s quarterly performance was affected by lower net investment income and exchange rate. Nevertheless, the downside was partly offset by higher sales in the U.S. unit.
Aflac Incorporated Price, Consensus and EPS SurpriseAflac Incorporated Price, Consensus and EPS Surprise
Aflac Incorporated price-consensus-eps-surprise-chart | Aflac Incorporated Quote
AFL’s Q1 Performance
Adjusted net investment income declined 1.2% year over year to $902 million in the quarter under review.
Net benefits and claims totaled $1.8 billion, which declined 5.8% year over year. Total acquisition and operating expenses decreased 1.5% year over year to $1.3 billion.
Pre-tax earnings increased to $1.2 billion from $145 million in the prior-year quarter.
Inside Aflac’s Segments
Aflac Japan: The segment’s adjusted revenues dipped 4.4% year over year to $2.2 billion in the first quarter and missed the Zacks Consensus Estimate of $2.3 billion. Net earned premiums of $1.6 billion slipped 6.4% year over year and missed the consensus mark by 3.1%.
Adjusted net investment income increased 0.9% year over year to $591 million. The unit’s pretax adjusted earnings rose 5.1% to $759 million but missed the consensus mark of $800.9 million.
New annualized premium sales advanced 25.5% year over year to $113 million on the back of solid sales of Anshin Palette, Miraito and Tsumitasu.
Aflac U.S.: Adjusted revenues of $1.8 billion grew 3.4% year over year and beat the Zacks Consensus Estimate by 0.3%. Net earned premiums advanced 3.5% year over year to $1.6 billion, attributable to higher sales. The metric beat the consensus mark of $1.5 billion.
Adjusted net investment income totaled $201 million, which inched down 0.5% year over year in the quarter under review. Pretax adjusted earnings of the segment increased 1.4% year over year to $363 million. The metric beat the consensus mark of $359.1 million.
The unit’s sales totaled $318 million, up 2.9% year over year, on the back of higher sales of group products.
Financial Position (As of March 31, 2026)
Aflac exited the first quarter with total investments and cash of $103.2 billion, down from the 2025-end level of $103.8 billion. Total assets of $116.3 billion decreased 0.2% from the year-end figure.
Adjusted debt amounted to $7.6 billion, down 1.2% from the figure as of Dec. 31, 2025. Adjusted debt to adjusted capitalization, excluding accumulated other comprehensive income, was 21.2%, which improved 20 basis points (bps) from the 2025-end level.
Story Continues
Total shareholders' equity of $30 billion advanced 1.6% from the 2025-end figure.
Adjusted book value per share increased 5.7% year over year to $54.96. Adjusted return on equity, excluding foreign currency impacts, was 16.4%, which improved 80 bps year over year.
AFL’s Capital Deployment
Aflac bought back shares worth $1 billion in the first quarter of 2026. Management paid a dividend of $315 million in the same quarter.
AFL’s 2026 Outlook
Aflac still expects a benefit ratio of 60-63% for the Aflac Japan unit in 2026. The metric for the Aflac U.S. unit is still projected to be in the 48-52% range.
The expense ratio for Aflac Japan is still estimated to be 20-23%. The same for Aflac U.S. is reiterated to be in the band of 36-39%.
Underlying earned premiums were likely to witness a year-over-year decline of 1-2% for the Japan unit in 2026. Net earned premiums for the U.S. unit were likely to be at the lower end of the 3-6% range.
The pretax profit margin for Aflac Japan is still estimated to be between 33% and 36%, and the same for Aflac U.S. is projected to be in the range of 17-20% for 2026.
AFL’s Zacks Rank
AFL currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
How Did Peers Perform?
Several companies in the insurance space, including RenaissanceRe Holdings Ltd. RNR, AMERISAFE, Inc. AMSF and The Hartford Insurance Group, Inc. HIG, have already reported their financial results for the March quarter of 2026. Here’s how they had performed:
RenaissanceRe reported first-quarter 2026 operating income of $13.75 per share, which surpassed the Zacks Consensus Estimate by 24.2%. The bottom line improved from the year-ago quarter’s operating loss of $1.49. Total operating revenues declined 16.6% year over year to $2.6 billion. The top line missed the consensus mark by 10.6%. RNR’s quarterly earnings were aided by a decline in expenses and strong underwriting performance in both segments. Improved combined ratio and fee income contributed to the upside. However, the upside was partly offset by lower net premiums earned across both segments.
AMERISAFE reported first-quarter 2026 adjusted earnings per share of 50 cents, which missed the Zacks Consensus Estimate of 52 cents. The bottom line declined 16.7% year over year. Operating revenues increased 7.9% year over year to $81.75 million but missed the consensus estimate by 0.9%. AMSF’s quarterly result was affected by higher expenses and weaker underwriting margins, with additional pressure from lower fee income and weaker investment income. Stronger premium growth partially offsets the downside.
Hartford posted first-quarter fiscal 2026 core earnings per share of $3.09, up 40.5% from $2.20 in the prior-year quarter. The figure missed the Zacks Consensus Estimate of $3.29 by 6.1%. Operating revenues totaled $5.09 billion, up 7% year over year, but missed the consensus mark by 2.1%. HIG’s weaker-than-expected results were caused by less favorable prior-year reserve development, higher expenses and pressure in Employee Benefits. The negatives were partially offset by high demand for expensive risk events, stronger investment income and a massive turnaround in Personal Insurance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Hartford Insurance Group, Inc. (HIG) : Free Stock Analysis Report
Aflac Incorporated (AFL) : Free Stock Analysis Report
RenaissanceRe Holdings Ltd. (RNR) : Free Stock Analysis Report
AMERISAFE, Inc. (AMSF) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Aflac opens new South Portland office to support Maine Paid Family and Medical Leave Program
May 1, 2026
Company brings services closer to home for more than 500,000 workers
COLUMBUS, Ga., May 1, 2026 /PRNewswire/ -- Working with the Maine Department of Labor and the state's Paid Family Medical Leave (PFML) Bureau, Aflac, the leading provider of supplemental health insurance in the U.S.1 and contracted administrator for the Maine PMFL program, announced the opening of a new office in South Portland, Maine. This fully staffed facility provides high-quality claims administration services for over 500,000 eligible workers in the state of Maine and the public and private sector employers participating in the program. The Maine PFML program will begin issuing benefits for the program as of May 1.
"We are honored to have been selected as the administrator of this important program and are excited to open this local office, demonstrating our commitment to the people of Maine now and for the foreseeable future," said Scott Beeman, senior vice president, Aflac Group Life, Disability and Absence Solutions.
"The launch of Maine's Paid Family and Medical Leave program marks a transformative moment for workers and families across our state. We have all been working hard, and we are deeply appreciative of the partnership with Aflac to ensure a successful launch and implementation. Their commitment to standing up a local office and delivering high-quality service reflects the level of care that Maine workers deserve," said Luke Monahan, director, Maine Paid Family and Medical Leave program.
Eligible workers in Maine can receive up to 12 weeks of paid time off within a benefit year to care for a family member with a serious health condition; to bond with a child after birth, fostering or adoption; to care for their own medical needs; to deal with the transition of a family member impending military deployment; or for safe leave. The leave does not need to be taken all at once.
Updates about the Maine Paid Family and Medical Leave program are posted at www.maine.gov/paidleave.
ABOUT AFLAC INCORPORATED Aflac Incorporated (NYSE: AFL), a Fortune 500 company, has helped provide financial protection and peace of mind for more than seven decades to millions of policyholders and customers through its subsidiaries in the U.S. and Japan. In the U.S., Aflac is the No. 1 provider of supplemental health insurance products.1 In Japan, Aflac Life Insurance Japan is the leading provider of cancer and medical insurance in terms of policies in force.2 The company takes pride in being there for its policyholders when they need us most, as well as being included in the World's Most Ethical Companies by Ethisphere for 20 consecutive years (2026) and Fortune's World's Most Admired Companies for 25 years (2026). In addition, the company became a signatory of the Principles for Responsible Investment (PRI) in 2021. To find out how to get help with expenses health insurance doesn't cover, get to know us at aflac.com or aflac.com/español. Investors may learn more about Aflac Incorporated and its commitment to corporate social responsibility and sustainability at investors.aflac.com under "Sustainability."
Story Continues
Group life, disability and absence services are provided by Continental American Insurance Company (CAIC); in New York, products and services are provided by American Family Life Assurance Company of New York; in California, coverage is offered by Continental American Life Insurance Company. Products may not be available in all states and may vary depending on state law.
1 LIMRA 2024 U.S. Supplemental Health Insurance Total Market Report 2 As of March 31, 2025, Aflac estimates based on company data.
Media contact: Jon Sullivan, 706-763-4813 or jsullivan@aflac.com
Analyst and investor contact: David A. Young, 706-596-3264, 800-235-2667 or dyoung@aflac.com
Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999
Aflac New York | 22 Corporate Woods Boulevard, Suite 2 | Albany, New York 12211
Continental American Insurance Company | Columbia, SC(PRNewsfoto/Aflac)Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/aflac-opens-new-south-portland-office-to-support-maine-paid-family-and-medical-leave-program-302760102.html
View Comments
- Aflac Q1 Earnings Miss Estimates on Lower Investment Income
May 1, 2026 · zacks.com
AFL misses Q1 estimates as lower investment income and FX pressure weigh on results, though U.S. sales strength and improved earnings partly offset the downside.
- Aflac opens new South Portland office to support Maine Paid Family and Medical Leave Program
May 1, 2026 · prnewswire.com
Company brings services closer to home for more than 500,000 workers COLUMBUS, Ga., May 1, 2026 /PRNewswire/ -- Working with the Maine Department of Labor and the state's Paid Family Medical Leave (PFML) Bureau, Aflac, the leading provider of supplemental health insurance in the U.S.1 and contracted administrator for the Maine PMFL program, announced the opening of a new office in South Portland, Maine.
